Alnylam Pharmaceuticals, Inc.

NasdaqGS:ALNY Stock Report

Market Cap: US$34.9b

Alnylam Pharmaceuticals Management

Management criteria checks 3/4

Alnylam Pharmaceuticals' CEO is Yvonne Greenstreet, appointed in Jan 2022, has a tenure of 3.33 years. total yearly compensation is $11.49M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth $6.40M. The average tenure of the management team and the board of directors is 3.8 years and 9.5 years respectively.

Key information

Yvonne Greenstreet

Chief executive officer

US$11.5m

Total compensation

CEO salary percentage10.91%
CEO tenure3.3yrs
CEO ownership0.02%
Management average tenure3.8yrs
Board average tenure9.5yrs

Recent management updates

We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

May 01
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

Recent updates

We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

May 01
We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21

Alnylam: Waiting For Regulatory Updates In March

Feb 13

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?

Jan 17
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment?

What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

Dec 16
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

Oct 27

Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Sep 12
Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?

Alnylam: HELIOS-B Success Priced In Already

Aug 30

Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Aug 04
Analysts Are Upgrading Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its Latest Results

Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

Aug 02
Broker Revenue Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher

RNAi: Winning In The Clinic, Now For The Market

Jun 25

Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation

Jun 03

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam's Huge Opportunity

Jan 12

CEO Compensation Analysis

How has Yvonne Greenstreet's remuneration changed compared to Alnylam Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$270m

Dec 31 2024US$11mUS$1m

-US$278m

Sep 30 2024n/an/a

-US$332m

Jun 30 2024n/an/a

-US$73m

Mar 31 2024n/an/a

-US$332m

Dec 31 2023US$9mUS$976k

-US$440m

Sep 30 2023n/an/a

-US$510m

Jun 30 2023n/an/a

-US$1b

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$5mUS$850k

-US$1b

Sep 30 2022n/an/a

-US$1b

Jun 30 2022n/an/a

-US$981m

Mar 31 2022n/an/a

-US$893m

Dec 31 2021US$9mUS$619k

-US$853m

Sep 30 2021n/an/a

-US$838m

Jun 30 2021n/an/a

-US$887m

Mar 31 2021n/an/a

-US$876m

Dec 31 2020US$3mUS$622k

-US$858m

Sep 30 2020n/an/a

-US$891m

Jun 30 2020n/an/a

-US$846m

Mar 31 2020n/an/a

-US$886m

Dec 31 2019US$3mUS$571k

-US$886m

Sep 30 2019n/an/a

-US$821m

Jun 30 2019n/an/a

-US$858m

Mar 31 2019n/an/a

-US$802m

Dec 31 2018US$3mUS$540k

-US$761m

Compensation vs Market: Yvonne's total compensation ($USD11.49M) is about average for companies of similar size in the US market ($USD14.05M).

Compensation vs Earnings: Yvonne's compensation has increased whilst the company is unprofitable.

CEO

Yvonne Greenstreet (61 yo)

3.3yrs

Tenure

US$11,492,970

Compensation

Dr. Yvonne L. Greenstreet, MBA, M.D., is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. She...

Leadership Team

NamePositionTenureCompensationOwnership
Yvonne Greenstreet
CEO & Director3.3yrsUS$11.49m0.018%
$ 6.4m
Phillip Sharp
Co-Founderno dataUS$503.79k0.20%
$ 71.4m
Jeffrey Poulton
CFO & Executive VP5.8yrsUS$3.79m0.020%
$ 6.9m
Kevin Fitzgerald
Executive VP6yrsUS$2.67m0.0078%
$ 2.7m
Pushkal Garg
Chief Medical Officer and Executive VP of Development & Medical Affairs10.6yrsUS$2.92m0.0013%
$ 453.5k
Tolga Tanguler
Executive VP & Chief Commercial Officer4.3yrsUS$2.75m0.0069%
$ 2.4m
Timothy Maines
Chief Technical Operations & Quality Officer2.3yrsno datano data
Piyush Sharma
Chief Ethics & Compliance Officer2.7yrsno datano data
Robert Hesslein
Executive VPless than a yearno datano data
Christine Lindenboom
Chief Corporate Communications Officerno datano datano data
Melissa McLaughlin
Chief Human Resources Officerno datano datano data
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

56yo

Average Age

Experienced Management: ALNY's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yvonne Greenstreet
CEO & Director3.6yrsUS$11.49m0.018%
$ 6.4m
Phillip Sharp
Co-Founder22.9yrsUS$503.79k0.20%
$ 71.4m
Muthiah Manoharan
Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board9.6yrsno datano data
Akshay Vaishnaw
Chief Innovation Officer & Member of the Scientific Advisory Boardno dataUS$3.32m0.018%
$ 6.2m
Peter Kellogg
Independent Director2.2yrsUS$486.98k0%
$ 0
Paul Schimmel
Member of the Scientific Advisory Boardno dataUS$516.04kno data
David E. Pyott
Independent Director9.4yrsUS$478.79k0.021%
$ 7.5m
Amy W. Schulman
Independent Chair of the Board10.8yrsUS$533.79k0.0086%
$ 3.0m
Markus Stoffel
Member of Scientific Advisory Boardno datano datano data
David Bartel
Member of Scientific Advisory Boardno datano datano data
Dennis Ausiello
Member of the Scientific Advisory Board & Independent Director13.1yrsUS$478.79k0.0028%
$ 973.3k
Colleen Reitan
Independent Director6.9yrsUS$491.29k0%
$ 0

9.5yrs

Average Tenure

69.5yo

Average Age

Experienced Board: ALNY's board of directors are considered experienced (9.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 00:05
End of Day Share Price 2025/05/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 61 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg